HomeGLAXF • OTCMKTS
add
GSK plc
Previous close
$29.40
Day range
$28.00 - $29.25
Year range
$15.54 - $31.48
Market cap
118.70B USD
Avg Volume
3.84K
P/E ratio
-
Dividend yield
-
Primary exchange
LON
In the news
Financials
Income Statement
Revenue
Net income
| (GBP) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 8.62B | 6.17% |
Operating expense | 4.57B | -0.28% |
Net income | 636.00M | 53.62% |
Net profit margin | 7.38 | 44.71% |
Earnings per share | — | — |
EBITDA | 2.50B | 35.38% |
Effective tax rate | 23.47% | — |
Balance Sheet
Total assets
Total liabilities
| (GBP) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.41B | -21.27% |
Total assets | 61.12B | 2.78% |
Total liabilities | 45.16B | -2.62% |
Total equity | 15.96B | — |
Shares outstanding | 4.01B | — |
Price to book | 7.21 | — |
Return on assets | 5.87% | — |
Return on capital | 10.70% | — |
Cash Flow
Net change in cash
| (GBP) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 636.00M | 53.62% |
Cash from operations | 2.28B | -2.19% |
Cash from investing | -933.00M | 16.62% |
Cash from financing | -856.00M | -1.66% |
Net change in cash | 448.00M | 19.47% |
Free cash flow | 1.15B | -49.69% |
About
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Founded
Dec 27, 2000
Website
Employees
68,629
